Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics plus oral immunotherapy for severe egg allergy in children
jRCTs041220087Active, not recruiting
- Sponsor
- National Hospital Organization
- Start
- Jan 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of Lactobacillus rhamnosus GG and bifidobacterium bifidum TMC3115 in egg allergy and food allergy (2 arms), sponsored by National Hospital Organization. Primary endpoint: Tolerance to 1/2 heated whole egg at 12 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
Lactobacillus rhamnosus GGbifidobacterium bifidum TMC3115
03
Conditions
egg allergyfood allergy
Beyond the preview
Go deeper on jRCTs041220087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220087.